EGFR and neoplasm: Patients treated with EGFR-TKI alone were more likely to have a N2–3 (51.4% TKI alone vs. 31.8% upfront RT; P = 0.018) and M1a (18.7% TKI alone vs. 0% upfront RT; P < 0.0001) stage tumour at diagnosis.